‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.